We are looking forward to connecting at the 42nd Annual JPM Healthcare Conference 2024 to discuss sozinibercept and its potential for future clinical, regulatory and commercial success. Both global pivotal trials in wet AMD (COAST and ShORe) are now over 80% enrolled and aim at confirming the superior efficacy outcomes observed in Opthea’s Phase 2b trial.
OMG, still over 80%... the enrollment is still too slow..At this rate, we may not see results until 26 , and multiple capital rasing
We are looking forward to connecting at the 42nd Annual JPM...
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
48.5¢ |
Change
-0.035(6.73%) |
Mkt cap ! $321.4M | |||
| Open | High | Low | Value | Volume |
| 50.5¢ | 50.5¢ | 47.5¢ | $314.0K | 642.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3270 | 48.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 49.5¢ | 9056 | 2 |
View Market Depth
| Last trade - 16.10pm 06/06/2024 (20 minute delay) ? |
|
|||||
|
Last
48.5¢ |
Change
-0.035 ( 6.73 %) |
||||
| Open | High | Low | Volume | ||
| 49.0¢ | 50.0¢ | 47.5¢ | 78801 | ||
| Last updated 15.59pm 06/06/2024 ? | |||||
| OPT (ASX) Chart |